124 results about "Cancer biomarkers" patented technology

The present application discloses an epigenetic marker for colon cancer.

Quantification of a target analyte is performed using a single sample to which amounts of the target analyte are added. Calibration is performed as part of quantification on the same sample. The target analyte is detectable and quantifiable using label free reagents and requiring no sample preparation. Target analytes include biomarkers such as cancer biomarkers, pathogenic Escherichia coli, single stranded DNA, and staphylococcal enterotoxin. The quantification process includes determining a sensor response of a sensor exposed to the sample and configured to detect the target analyte. Sensor responses are determined after sequential additions of the target analyte to the sample. The amount of target analyte detected by the sensor when first exposed to the sample is determined in accordance with the multiple sensor responses.

The present disclosure relates to methods for determining the presence, activity, and/or concentrations of certain cancer biomarkers and their use in determining the presence of cancer.

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

A method of evaluating a probability a subject has a cancer, diagnosing a cancer and/or monitoring cancer progression comprising: a. measuring an amount of a biomarker selected from the group consisting of CUZD1 and/or LAMC2 and/or the group CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, IAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, KLK3, NPY, PSCA, RLN1, SLC45A3, DSP, GP73, DSG2, CEACAM7, CLCA1, GPA33, LEFTY1, ZG16, IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC, TMEM100, NPY, PSCA, RLN1 and/or SLC45A3 in a test sample from a subject with cancer; wherein the cancer is pancreas cancer if CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, LAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, DSP, GP73 and/or DSG2 is selected; the cancer is colon cancer if CEACAM7, CLCA1, GPA33, LEFTY1 and/or ZG16 is selected, the cancer is lung cancer if IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC and/or TMEM100 is selected; or the cancer is prostate cancer if NPY, PSCA, RLN1 and/or SLC45A3 is selected; b. comparing the measured amount to a control and detecting an increase in the amount of the biomarker compared to control; and c. identifying the subject as having or having an increased probability of having the cancer when an increase in the biomarker compared to control is detected.

The present invention provide a system and a method for detection of cancer, by producing a serum proteome standard by an image mining technique, and provide cancer-specific biomarkers. Disclosed is a method of analyzing cancer, comprising the steps of transforming serum proteomes from normal individuals and individuals having cancer into two-dimensional images, and constructing a database consisting of the proteome standard by an image mining technique; inputting a serum proteome from a subject of interest, transforming the serum proteome into a image and comparing the structure of the serum proteome pattern of the subject with the proteome standard and determining whether the serum proteome of the subject is normal or abnormal. The system and method for cancer analysis facilitates detection of cancer by constructing a database from a plurality of serum proteome using an image technique and comparing serum proteome of a subject with a proteome standard.

The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD⁴⁺, CD⁸⁺ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

The invention relates to a targeting qualitative and quantitative metabonomic technical analysis method used for screening cancer biomarkers based on the LC-MS/MS technology. The method is characterized in that a structure prediction function of multi-reaction monitoring-dependent information acquisition-enhanced daughter ion detection on correlative metabolites and a structure identification function of a high-resolution mass spectrum are predicted by fully utilizing a multi-reaction monitoring quantitation function of the high performance liquid-tandem mass spectrum, and the analysis methodsuitable for screening biomarkers of various cancers is formed. The method has the advantages of high flux, good stability and high adaptability, and improves sensitivity and accuracy of screening andfinding of metabonomic biomarkers.

The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD⁴⁺, CD⁸⁺ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

The invention provides a preparing method and application of mimic enzyme with double catalysis functions based on a hemin mediation gold mineralization path. The one-pot type in-situ synthesis method is adopted, the hemin and chloroauric acid are mixed under the alkaline condition, then gold in-situ biological mineralization is achieved with the hemin as a reducing agent and a stabilizing agent, and a Hemin-AuNCs compound with Hemin peroxidase catalysis and gold catalysis activity is prepared. The function of a nano wire of the Hemin-AuNCs compound is brought into play, the electronic transmission capability of the Hemin catalysis reaction is promoted, meanwhile, the adsorption capability for a substrate is enhanced, and the catalysis activity of the Hemin-AuNCs compound is obviously higher than that of common Hemin by four or more times. Complex photoelectric instrument usage is not involved in the preparing method, and the beneficial effects that the catalysis activity is high, operation is simple, response is fast and cost is low are achieved. The cancer biomarker alpha fetoprotein immunoassay serves as the example, the Hemin-AuNCs compound is applied to marking of an AFP antibody, then, the enzyme linked immunosorbent assay is adopted, and high-sensitivity detection on the cancer biomarker alpha fetoprotein in blood is achieved through the enzymatic catalysis and gold catalysis silver deposition signal amplification path.

The invention discloses a luminol and trisruthenium-based potential-resolved electrochemiluminescence detection method. Luminal and trisruthenium are used as luminescent probes. During detection, an ITO (indium tin oxide) electrode is used as a working electrode for luminescence detection, a silver-silver chloride electrode is used as a reference electrode, a potassium electrode is used as a counter electrode, and a luminescent signal from luminol is detected by performing scanning from 0.6V to 0.0V; peroxydisulfate and an excessive amount of luminol are added into a detection system, and a luminescent signal from trisruthenium is detected by performing scanning from 0.0V to -1.0V. The invention also discloses a simple and effective method for simultaneously detecting two cell surface cancer biomarkers. According to the methods, two antigens on the surfaces of cells can be analytically detected by one step by double-tagging and potential resolving methods, the mutual interference of signals under different potentials is eliminated, and carcinoembryonic antigens and alpha fetoprotein antigens on surfaces of cells are successfully detected at the same time.

Using gene expression analysis, specific biomarker genes and gene products have been identified which are activated in transformed cells, but suppressed in nontransformed cells; or suppressed in transformed cells, but activated in transformed cells affected by Contact Normalization. Thus, the present invention features compositions and methods for detecting, diagnosing, treating and prognosing cancer.